Insmed Incorporated (NASDAQ:INSM) COO Sells $57,460.06 in Stock

Insmed Incorporated (NASDAQ:INSMGet Rating) COO Roger Adsett sold 3,194 shares of the stock in a transaction that occurred on Tuesday, January 10th. The shares were sold at an average price of $17.99, for a total transaction of $57,460.06. Following the sale, the chief operating officer now directly owns 135,487 shares of the company’s stock, valued at $2,437,411.13. The sale was disclosed in a document filed with the SEC, which is available through this link.

Roger Adsett also recently made the following trade(s):

  • On Thursday, January 5th, Roger Adsett sold 3,044 shares of Insmed stock. The shares were sold at an average price of $19.75, for a total transaction of $60,119.00.
  • On Tuesday, November 22nd, Roger Adsett sold 11,855 shares of Insmed stock. The shares were sold at an average price of $18.80, for a total transaction of $222,874.00.

Insmed Stock Performance

INSM stock opened at $19.45 on Friday. The firm has a market cap of $2.64 billion, a price-to-earnings ratio of -5.34 and a beta of 1.49. Insmed Incorporated has a twelve month low of $16.41 and a twelve month high of $28.94. The company has a quick ratio of 4.11, a current ratio of 4.59 and a debt-to-equity ratio of 18.24. The business’s fifty day simple moving average is $19.06 and its two-hundred day simple moving average is $21.43.

Insmed (NASDAQ:INSMGet Rating) last announced its quarterly earnings data on Thursday, October 27th. The biopharmaceutical company reported ($1.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.20). The company had revenue of $67.73 million for the quarter, compared to the consensus estimate of $68.02 million. Insmed had a negative net margin of 179.37% and a negative return on equity of 319.03%. Analysts predict that Insmed Incorporated will post -3.65 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. The Goldman Sachs Group reduced their price objective on Insmed from $44.00 to $39.00 and set a “buy” rating on the stock in a research note on Monday, January 9th. Mizuho initiated coverage on shares of Insmed in a research report on Thursday, December 8th. They set a “buy” rating and a $28.00 price objective for the company. Cantor Fitzgerald decreased their target price on shares of Insmed from $53.00 to $49.00 and set an “overweight” rating on the stock in a research report on Tuesday, October 25th. Cowen reduced their price objective on Insmed from $56.00 to $53.00 and set an “outperform” rating on the stock in a research note on Friday, October 21st. Finally, StockNews.com assumed coverage on Insmed in a research note on Wednesday, October 12th. They issued a “hold” rating for the company. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Insmed has an average rating of “Moderate Buy” and a consensus target price of $43.55.

Institutional Investors Weigh In On Insmed

Several large investors have recently modified their holdings of INSM. Hudson Bay Capital Management LP lifted its holdings in Insmed by 390.2% during the second quarter. Hudson Bay Capital Management LP now owns 784,300 shares of the biopharmaceutical company’s stock worth $15,466,000 after buying an additional 624,300 shares during the period. Tang Capital Management LLC bought a new stake in Insmed during the third quarter valued at about $10,770,000. Assenagon Asset Management S.A. grew its stake in Insmed by 56.6% in the second quarter. Assenagon Asset Management S.A. now owns 1,258,920 shares of the biopharmaceutical company’s stock valued at $24,826,000 after purchasing an additional 455,186 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in shares of Insmed by 2.3% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 16,222,623 shares of the biopharmaceutical company’s stock valued at $319,910,000 after buying an additional 364,362 shares in the last quarter. Finally, Nuveen Asset Management LLC grew its position in shares of Insmed by 71.2% in the 3rd quarter. Nuveen Asset Management LLC now owns 824,216 shares of the biopharmaceutical company’s stock worth $17,754,000 after buying an additional 342,694 shares during the last quarter. Institutional investors own 92.83% of the company’s stock.

Insmed Company Profile

(Get Rating)

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE┬« (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

Read More

Insider Buying and Selling by Quarter for Insmed (NASDAQ:INSM)

Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.